• CROSSJECT signs a partnership agreement for ZENEO® Methotrexate in China

    CROSSJECT has completed a non-exclusive partnership agreement in China with Xi'an Xiantong Pharmaceutical Research to promote and sale ZENEO® Methotrexate. The agreement with this well-established player in its domestic market allows to estimate a turnover of around € 360 million generated by royalties for ZENEO® Methotrexate over 10 years according to the terms of the contract, to which the profits from the supply contract will be added. "By positioning ZENEO® Methotrexate on a fast growing market potentially representing very big volumes for our drugs, we are in perfect conditions to create value for CROSSJECT and their shareholders," said Patrick Alexandre, President and founder of CROSSJECT. 

    Read more
  • Bpifrance supports the development of Crossject’s products portfolio

    CROSSJECT announces that it has been awarded a grant of €6.7 million by Bpifrance, repayable over three years, as part of the Industrial Projects of the Future (Projets Industriels d’Avenir or PIAVE) scheme. This funding gives CROSSJECT the resources to develop three new proprietary drugs for use in emergency situations.

    Read the press release

    Read more


  • 04/20/2016

    Meet us at BioTrinity 2016

    Crossject will be present at BioTrinity 2016, the event dedicated to partnerships that brings together leaders from the biopharmaceutical industry. Meet us in London, April 25th to 27th.
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more
  • 04/10/2016

    Kepler Cheuvreux Biotech Days

    Meet us in Paris, June 15th and 16th during the "Kepler Cheuvreux Biotech Days".
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more


Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos